FDA Exclusivity Protections Blocking ‘Me Too’ Product Challenged In Lawsuit
This article was originally published in The Pink Sheet Daily
Executive Summary
Veloxis sues FDA after agency declines to approve to its extended-release immunosuppressant, Envarsus XR, until exclusivity for Astellas’ Astagraf XL expires in 2016.
You may also be interested in...
Keeping Track Of The US FDA's Final Approvals Of 2018
A roundup of the US FDA's drug approvals in the final weeks of 2018.
Astellas Finally Wins FDA Approval For Prograf Successor
Female mortality rate among liver transplant patients had been a major obstacle to approval for extended-release tacrolimus, which was first filed in 2005. But the once-daily drug is now approved for kidney transplant patients.
Paying For Gene Therapy: Biggest Cost Challenges Two To Three Years Away?
Only about one-quarter of the 40 gene therapies projected to launch by the end of 2025 would have potential US patient populations of more than 50,000. But a handful of treatments could target millions of individuals.